RecruitingPhase 4NCT05992480
REVIVE (Response to the Ebola Virus Vaccine)
Studying Ebola hemorrhagic fever
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Tulane University
- Principal Investigator
- John Schieffelin, MDTulane University
- Intervention
- rVSVDG-ZEBOV-GP Ebola Virus Vaccine (ERVEBO)(biological)
- Enrollment
- 40 enrolled
- Eligibility
- 18-100 years · All sexes
- Timeline
- 2025 – 2026
Study locations (1)
- Kenema Government Hospital, Kenema, Eastern Province, Sierra Leone
Collaborators
Kenema Government Hospital · Merck Sharp & Dohme LLC
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05992480 on ClinicalTrials.govOther trials for Ebola hemorrhagic fever
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE2NCT06803342A Trial to Evaluate Safety, Tolerability, and Immune Responses of an Investigational Monovalent Chimpanzee Adenoviral Vectored Sudan Ebolavirus Vaccine in Healthy AdultsAlbert B. Sabin Vaccine Institute
- RECRUITINGPHASE3NCT06126822Safety and Immunogenicity of Ervebo® and Zabdeno® Booster Vaccines Against Ebola Virus Following Previous Vaccination with the Zabdeno/Mvabea® or Ervebo® Vaccine Schedules in DRCInstitute of Tropical Medicine, Belgium
- ACTIVE NOT RECRUITINGPHASE2NCT06100913Immunology of Ebola VaccineEmory University